Recent research, led by Steven Katz, M.D., M.P.H., Professor of Medicine and Health Management at the University of Michigan, has found that a low percentage of individuals are undergoing genetic testing for cancer, despite its potential benefits. Germline genetic testing involves sequencing inherited DNA and is recommended for cancer patients to guide personalized treatment and identify relatives who may benefit from tailored cancer screening and prevention. Testing rates were particularly low among Black, Hispanic, and Asian patients. The researchers expressed surprise at these low rates, given the growing evidence of the benefits of genetic testing for patients and their families. They highlighted the need for improved strategies and tools to ensure that genetic oncology advancements are effectively implemented to improve health outcomes for patients and their families.
